Utility of the second-generation curcumin analogue RL71 in canine histiocytic sarcoma.

Barnaby Kelly, Douglas Thamm, Rhonda J Rosengren

Open access · hybridAbstract read

In one paragraph

Article in Veterinary research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.5field-weighted citation impact, top 33% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Barnaby KellyDepartment of Pharmacology and Toxicology, Unversity of Otago, 18 Frederick Street, Dunedin, 9085, New Zealand.ORCID http://orcid.org/0009-0008-5766-0620

Douglas ThammFlint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.ORCID http://orcid.org/0000-0002-8914-7767

Rhonda J RosengrenDepartment of Pharmacology and Toxicology, Unversity of Otago, 18 Frederick Street, Dunedin, 9085, New Zealand. rhonda.rosengren@otago.ac.nz.ORCID http://orcid.org/0000-0002-9718-0719

University of Otago · NZColorado State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Canine histiocytic sarcoma is an aggressive cancer, with a high rate of metastasis. Thus, novel therapeutic approaches are needed. Synthetic analogues of curcumin have elicited potent anti-cancer activity in multiple in vitro and in vivo models of human cancer. Furthermore, the compound 3,5-bis(3,4,5-trimethoxybenzylidene)-1-methylpiperidine-4-one (RL71) has recently exhibited potent cell cycle arrest and apoptotic induction in a canine osteosarcoma cell line. To determine its potency in canine histiocytic sarcoma cells, cell viability of DH82 and Nike cells was measured using the sulforhodamine B assay. Flow cytometry was then used to analyse both cell cycle distribution and apoptosis. Of the five curcumin analogues examined, RL71, had the highest potency with EC

Indexed as

Antineoplastic AgentsCurcuminDog DiseasesHistiocytic SarcomaAnimalsApoptosisCell Line, TumorDogsHumansAntineoplastic AgentsCurcuminCanine histiocytic sarcomaCell cycle arrest and apoptosisCurcumin analogues

Identifiers

PMID37597087

DOI10.1007/s11259-023-10201-2

PMCPMC10811103

OpenAlexW4386000161

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.